UPDATE - Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and…
Read the full articleYou might also wanna read
Endevica spinout Kalohexis submits confidential IPO filing to develop obesity challenger to GLP-1s
Clinical-stage Kalohexis is readying a public listing to support its obesity and cancer cachexia treatments.
Sun Pharma gets go-ahead to sell generic semaglutide in South Africa
The approval is to treat Type II diabetes
Navigating the Gray Area: The Unregulated Surge of Unique GLP-1 and GLP-1/GIP Products
Purpose: To identify unique compounded semaglutide and tirzepatide products that existed after the shortage grace period ended and to assess
Health tech companies rush to market 'GLP-1 ready' products as weight loss drug trend grows
In this week’s Optimizer, we take a look at how health tech companies are starting to incorporate features ‘built for GLP-1’ users.
theverge.com·1mo ago
GSK Joins PRECISE–SG100K PCC as 5th Pharma Partner
GSK’s participation in the PRECISE–SG100K Pharma Pre Competitive Consortium (PCC) reflects growing industry recognition of Singapore’s Natio
Demand for GLP-1 weight-loss and diabetes drugs plateaus, says industry tracker
A total of 31 generic semaglutide brands contributed to 82 per cent of the unit sales of the month
Comments
Sign in to join the conversation.
No comments yet. Be the first.